Genmab — Januar 2018
-
JNJ will present at JPM on Monday already, with a webcast
https://www.jnj.com/media-center/press-releases/johnson-johnson-to-participate-in-36th-annual-jp-morgan-health-care-conference -
Virker som et vildt sats, dog med frigivelse af købesummen forudsat effekt. Pipelinen http://impactbiomedicines.com/fedratinib.html#pipeline
-
Novo skulle iflg Medwatc være interesseret i Ablynx til 20 mia dkk http://ablynx.com/our-company/overview/
-
-
God morgen.

-
God morgen. Blood journal: Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL)
http://www.bloodjournal.org/content/early/2018/01/04/blood-2017-07-794214?sso-checked=true -
CD38 antibodies in multiple myeloma: back to the future http://www.bloodjournal.org/content/131/1/13/tab-article-info
-
"Novo Nordisk koncernfinansdirektør, Jesper Brandgaard, siger mandag morgen på en telekonference, at medicinalkoncernen er klar til at ændre sit købstilbud, hvis forhandlinger med bestyrelsen i Ablynx afslører, at der er mere værdi i det belgiske biotekselskab"
-
Tror ikke de har givet op endnu, men det ser ikke i skrivende stund ud til at de kan presse prisen ned, da der er fint med købere
-
AB har i hvert fald smidt 13.5k aktier her den første time
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind